Sarah Premji, MD (@SPremji7866) ranks #20 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 9 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HER2CLIMB-05, ASCENT03, ASCENT-04. CMS Open Payments lists $592 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- Breast Cancer: US #20 · 9 physicians engaged
- Leading physician voice: #3 of 19 physicians on HER2CLIMB-05
- CMS Open Payments lists $592 in 2025 general payments.
This Month
What Sarah Premji, MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Sarah Premji, MD
Physicians who reposted Sarah Premji, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #20 | — | 9 | 13 | Full ranking |
Trials Sarah Premji, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HER2CLIMB-05 | 2 | #3 of 19 | Oct 7, 2026 |
| ASCENT03 | 1 | #9 of 19 | Jun 2, 2026 |
| ASCENT-04 | 1 | #15 of 24 | Jun 2, 2026 |
Sarah Premji, MD on HER2CLIMB-05
Absolutely incredible, 11 approvals in half of a year! Tucatinib is now approved in front line maintainence for HER2+ MBC a win for patients! Kudos to @ErikaHamilton9 and team for their study of HER2CLIMB05! @SCRIOncology @SarahCannonDocs https://t.co/jy0utGuo1i
@ErikaHamilton9 beautifully presents additional efficacy and safety from HER2CLIMB05, at median follow up of 23 months mPFS was prolonged by 9 month. In HR- mPFS 12.6 mo improved to 24.9 mos, in HR+, mPFS improved from 18.1 mo to 25 mo, those with and without baseline brains mets https://t.co/PWVzRDvWlY
Sarah Premji, MD on ASCENT03
#ASCO26 this morning we heard about several subsequent measures in ASCENT03, ASCENT04 and TB02 including PFS-2, great to see this data, however Meredith Regan reviews that significant caution should be used in interpretation of PFS-2, notably is not consistent and well defined, https://t.co/FSjTPKlfXb
Sarah Premji, MD on ASCENT-04
#ASCO26 this morning we heard about several subsequent measures in ASCENT03, ASCENT04 and TB02 including PFS-2, great to see this data, however Meredith Regan reviews that significant caution should be used in interpretation of PFS-2, notably is not consistent and well defined, https://t.co/FSjTPKlfXb
Sarah Premji, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Dr. Elizabeth Lee reviews gapped schedule olaparib plus DS-8201a (T-DXd) in HER2 expressing tumors, endometrial and ovarian cancers, ORR 54%, mDOR 11.2 months, with durable disease control, sound rationale supporting synergism in a gapped schedule based on mechanism #AACR26 @AACR @DanaFarber
Good morning San Diego! Beautiful place to connect, collaborate and see some exciting science! #AACR26 @AACR #FDAAACRfellow @SarahCannonDocs @SCRIOncology https://t.co/FGKVyBVslf
Robust discussion around lower US enrollment on global trials, barriers and some potential solutions at #AACR26 @AACR https://t.co/Ef6BUqbE21
Industry Payments
CMS Open Payments · 2025 general payments
$592 across 21 payments